Your browser doesn't support javascript.
loading
Prime editing in mice with an engineered pegRNA.
Salem, Amr R; Bryant, W Bart; Doja, Jaser; Griffin, Susan H; Shi, Xiaofan; Han, Weihong; Su, Yunchao; Verin, Alexander D; Miano, Joseph M.
Afiliación
  • Salem AR; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America. Electronic address: asalem@augusta.edu.
  • Bryant WB; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Doja J; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Griffin SH; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Shi X; Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Han W; Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Su Y; Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Verin AD; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
  • Miano JM; Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States of America.
Vascul Pharmacol ; 154: 107269, 2024 03.
Article en En | MEDLINE | ID: mdl-38158001
ABSTRACT
CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3'-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Edición Génica Límite: Animals Idioma: En Revista: Vascul Pharmacol Asunto de la revista: ANGIOLOGIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Edición Génica Límite: Animals Idioma: En Revista: Vascul Pharmacol Asunto de la revista: ANGIOLOGIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article